A Phase I/II Trial of Bevacizumab (Avastin), Erlotinib (Tarceva), and Imatinib (Gleevec) in the Treatment of Patients With Advanced Renal Cell Carcinoma
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 94
- 主要终点
- Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment
研究概览
简要总结
This phase I/II trial will evaluate the bevacizumab/erlotinib combination with the addition of imatinib (Gleevec). The combined inhibition greatly enhances the anti-tumor effects. Although the safety of the bevacizumab/erlotinib/imatinib combination has not yet been demonstrated, the mild to moderate side effects of all of these agents are not predicted to cause prohibitive toxicity. A brief phase I portion will be included in this trial, to optimize doses of the 3 agents prior to proceeding with the phase II trial.
详细描述
Upon determination of eligibility, patients will be receive:
Bevacizumab + Erlotinib + Imatinib
A brief phase I dose escalation study will be performed to define the imatinib dose that will be used.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be included in this study, you must meet the following criteria:
- •Metastatic or unresectable clear cell renal carcinoma confirmed by biopsy
- •Previous nephrectomy is required
- •Maximum of 1 previous systemic regimen for metastatic disease.
- •Able to perform activities of daily living with minimal assistance
- •Measurable disease
- •Adequate bone marrow, liver and kidney
- •Written informed consent.
排除标准
- •Age < 18 years
- •Treatment with more than 1 previous systemic regimen
- •History of heart attack within 6 months
- •Clinically significant cardiovascular disease
- •Moderate to severe vascular disease.
- •Active brain metastases.
- •History or evidence by physical examination of brain tumor
- •Seizures not controlled with standard medical therapy
- •history of stroke or other serious disorders of the nervous system
- •Clinical history of coughing or vomiting blood within the past 3 months.
- •PEG tubes or G tubes
- •Chronic therapy with NSAIDS or other platelet inhibitors
- •Proteinuria
- •Nonhealing wound, ulcer, or long bone fracture
- •Clinical evidence or history of a bleeding disorder
- •Requiring full dose anticoagulation with coumadin
- •Receiving chronic steroid therapy
- •Significant medical conditions.
- •Tumors other than clear cell
- •History of stroke within 6 months.
- •History of abdominal fistula,perforation,or abscess within 6 months.
- •Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
研究组 & 干预措施
Intervention
In the phase I portion:
Bevacizumab 10 mg/kg slow IV infusion on days 1 and 15 of each 28-day course
Erlotinib 150 mg orally daily
Imatinib 300 mg orally daily or 400 mg orally daily
In the phase II portion:
Bevacizumab 10 mg/kg 30-60 minute IV infusion on days 1 and 15 of every 28 day cycle
Erlotinib 150 mg orally daily
Imatinib 400 mg orally daily
干预措施: Bevacizumab (Drug)
Intervention
In the phase I portion:
Bevacizumab 10 mg/kg slow IV infusion on days 1 and 15 of each 28-day course
Erlotinib 150 mg orally daily
Imatinib 300 mg orally daily or 400 mg orally daily
In the phase II portion:
Bevacizumab 10 mg/kg 30-60 minute IV infusion on days 1 and 15 of every 28 day cycle
Erlotinib 150 mg orally daily
Imatinib 400 mg orally daily
干预措施: Erlotinib (Drug)
Intervention
In the phase I portion:
Bevacizumab 10 mg/kg slow IV infusion on days 1 and 15 of each 28-day course
Erlotinib 150 mg orally daily
Imatinib 300 mg orally daily or 400 mg orally daily
In the phase II portion:
Bevacizumab 10 mg/kg 30-60 minute IV infusion on days 1 and 15 of every 28 day cycle
Erlotinib 150 mg orally daily
Imatinib 400 mg orally daily
干预措施: Imatinib (Drug)
结局指标
主要结局
Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment
时间窗: 18 months
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease
时间窗: 18 months
Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death
时间窗: 24 months
次要结局
未报告次要终点